| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_623b76f85903a005542eccff080bb548
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f9090d36b1bc0835b72e23da33af9f88 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-385
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 |
| filingDate |
2008-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba2abb82a9141349721dbf5cc3922807 |
| publicationDate |
2014-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8722013-B2 |
| titleOfInvention |
Use of R(+)-alpha-lipoic acid for cryptogenic neuropathy |
| abstract |
The present invention relates to the use of R(+)-alpha-lipoic acid ((R)-5-(1,2-dithiolan-3-yl)valeric acid) and/or of a physiologically acceptable derivative of this compound for cryptogenic neuropathy. |
| priorityDate |
2007-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |